Safety and efficacy of sotagliflozin in patients with type II diabetes mellitus and chronic kidney disease: a meta-analysis of randomized controlled trials.
Rafael Dos Santos BorgesGustavo de Oliveira AlmeidaVinícius Freire Costa AlvesThiago Faraco NienkotterEdmundo Damiani BertoliAna Cristina Dos Santos LopesPublished in: Journal of nephrology (2023)
In patients with T2DM and CKD, Sotagliflozin appears to be effective for glycemic control and weight loss. Although the medication seemed safe concerning mortality and cardiovascular events, it induced estimated glomerular filtration rate reduction, and was associated with a higher risk of genital mycotic infections, diarrhea, and volume depletion.
Keyphrases
- glycemic control
- cardiovascular events
- weight loss
- chronic kidney disease
- end stage renal disease
- type diabetes
- coronary artery disease
- bariatric surgery
- blood glucose
- cardiovascular disease
- roux en y gastric bypass
- high glucose
- gastric bypass
- systematic review
- diabetic rats
- insulin resistance
- healthcare
- endothelial cells
- emergency department
- adverse drug
- metabolic syndrome
- clostridium difficile
- skeletal muscle
- peritoneal dialysis
- risk factors
- physical activity
- electronic health record